

SUPPLEMENTARY MATERIAL

RESULTS

Table S1. Drugs included in reference groups.

Reference group	Drugs
Dipeptidyl peptidase-4 inhibitors (DPP-4is)	Alogliptin, linagliptin, saxagliptin, sitagliptin, and vildagliptin
Insulins	Insulin aspart, bovine insulin, insulin degludec, insulin detemir, insulin glargine, insulin glulisine, human insulin, insulin lispro, insulin glargine/lixisenatide, porcine insulin, insulin zinc, and insulin aspart/ insulin degludec
Other SGLT2-inhibitors	Canagliflozin, empagliflozin, and ertugliflozin




Figure S1. Trend of ketoacidosis adverse events with dapagliflozin for each type of diabetes mellitus.

*No case of ketoacidosis was reported in 2012

T1DM: type 1 diabetes mellitus, T2DM: type 2 diabetes mellitus, NCDM: not classifiable diabetes mellitus




Figure S2. ketoacidosis adverse events for type of diabetes mellitus.

T1DM: type 1 diabetes mellitus, T2DM: type 2 diabetes mellitus, NCDM: not classifiable diabetes mellitus




Figure S3. ROR of ICSRs with ketoacidosis adverse events for dapagliflozin compared to canagliflozin in all diabetes mellitus cases.




Figure S4. ROR of ICSRs with ketoacidosis adverse events for dapagliflozin compared to ertugliflozin in all diabetes mellitus cases.




Figure S5. ROR of ICSRs with ketoacidosis adverse events for dapagliflozin compared to empagliflozin in all diabetes mellitus cases.




Figure S6. ROR of ICSRs with ketoacidosis adverse events for dapagliflozin compared to empagliflozin in T1DM.




Figure S7. ROR of ICSRs with ketoacidosis adverse events for dapagliflozin compared to canagliflozin in T1DM.